ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 1999
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue repair. Key products include ORTHOVISC (human osteoarthritis, marketed internationally; U.S. clinical trial ongoing), HYVISC (equine osteoarthritis), and AMVISC/AMVISC Plus (ophthalmic surgery, manufactured for Bausch & Lomb Surgical).

Key Financial Metrics

Liquidity: As of June 30, 1999, the company held approximately $21.0 million in cash, cash equivalents, and investments. Management believes these funds are sufficient to meet operating requirements for at least the next 24 months.

Material Changes vs. Prior Period

• Revenue: Product revenue increased 21.1% ($654,000) for the quarter and 19.2% ($1.125 million) for the six months compared to the prior year periods, driven primarily by increased sales of ORTHOVISC. Total revenue decreased for the quarter due to the absence of a $1.5 million licensing payment received in the prior year.
• Net Income: Net income decreased significantly to $406,898 for the quarter (from $2.2 million) and $751,647 for the six months (from $2.8 million). This decline is attributed to the lack of the prior year licensing payment and increased operating expenses.
• Operating Expenses:
  • R&D: Increased 138% for the quarter and 83% for the six months, primarily due to costs associated with the ORTHOVISC clinical trial.
  • SG&A: Increased 14.6% for the quarter and 25.9% for the six months, driven by ORTHOVISC marketing costs, additional staffing, and stock option amortization.
• Cash Flow: Net cash provided by operating activities decreased to $577,089 for the six months ended June 30, 1999, compared to $1.68 million in the prior year. Net cash used in investing activities increased to $4.62 million, largely due to a $5.63 million increase in long-term investments and $781,000 in capital expenditures for manufacturing expansion.

Guidance, Outlook, and Risks

• Outlook: Management expects R&D expenses to increase substantially in 1999, with an estimated $2.5 million expenditure for the ORTHOVISC clinical trial. The company anticipates spending an additional $1.219 million on capital expenditures to complete manufacturing facility expansion, which should provide adequate capacity through 2003.
• Regulatory Status: ORTHOVISC is approved in Canada, Europe, Turkey, Israel, and Iceland. In the U.S., it is limited to investigational use. A Phase III clinical trial commenced in late April 1999 following an FDA determination that the previous PMA application was not approvable without additional data.
• Key Risks:
  • Customer Concentration: Sales to Bausch & Lomb Surgical accounted for 52.0% of product revenue in Q2 1999 and 59.7% for the six-month period. The supply agreement expires in 2001.
  • Regulatory Approval: No assurance that the FDA will approve the PMA for ORTHOVISC on a timely basis or at all. Failure to obtain approval could materially adversely affect operations.
  • Profitability: While profitable in 1997 and 1998, the company had an accumulated deficit of approximately $929,000 as of June 30, 1999. Sustained profitability is uncertain.
  • Patent Interference: A third party has initiated a patent interference proceeding regarding the Company's patent for INCERT (adhesion prevention), which could impact future marketing rights.

Investor Verification Checklist

• Customer Dependency: Verify the stability of the relationship with Bausch & Lomb Surgical, which represents over half of product revenue.
• Regulatory Timeline: Monitor the progress and results of the U.S. Phase III clinical trial for ORTHOVISC and the FDA's subsequent PMA review timeline.
• Cash Burn Rate: Assess whether the $21 million in liquid assets will sustain operations through the estimated $2.5 million clinical trial cost and manufacturing expansion without additional financing.
• Patent Status: Track the outcome of the patent interference proceeding regarding the INCERT product.
• Manufacturing Capacity: Confirm the completion of the manufacturing facility expansion and its impact on future production capabilities.